Roivant Sciences Ltd (NASDAQ: ROIV) on Thursday, soared 1.30% from the previous trading day, before settling in for the closing price of $10.02. Within the past 52 weeks, ROIV’s price has moved between $8.73 and $13.06.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 29.37% annually for the last half of the decade. The company achieved an average annual earnings per share of -105.88%. With a float of $438.67 million, this company’s outstanding shares have now reached $719.63 million.
In an organization with 908 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 89.03%, operating margin of -1027.4%, and the pretax margin is -594.75%.
Roivant Sciences Ltd (ROIV) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Roivant Sciences Ltd is 38.52%, while institutional ownership is 68.69%. The most recent insider transaction that took place on Mar 24 ’25, was worth 4,701,052. In this transaction President & COO of this company sold 434,478 shares at a rate of $10.82, taking the stock ownership to the 1,127,290 shares. Before that another transaction happened on Mar 20 ’25, when Company’s President & COO sold 315,522 for $11.06, making the entire transaction worth $3,489,673. This insider now owns 959,457 shares in total.
Roivant Sciences Ltd (ROIV) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.25 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -105.88% per share during the next fiscal year.
Roivant Sciences Ltd (NASDAQ: ROIV) Trading Performance Indicators
Roivant Sciences Ltd (ROIV) is currently performing well based on its current performance indicators. A quick ratio of 37.91 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 74.24.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.14, a number that is poised to hit -0.26 in the next quarter and is forecasted to reach -1.12 in one year’s time.
Technical Analysis of Roivant Sciences Ltd (ROIV)
Let’s dig in a bit further. During the last 5-days, its volume was 5.69 million. That was inferior than the volume of 5.8 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 88.02%. Additionally, its Average True Range was 0.43.
During the past 100 days, Roivant Sciences Ltd’s (ROIV) raw stochastic average was set at 33.77%, which indicates a significant decrease from 92.81% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 53.26% in the past 14 days, which was higher than the 35.03% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $10.40, while its 200-day Moving Average is $11.25. However, in the short run, Roivant Sciences Ltd’s stock first resistance to watch stands at $10.24. Second resistance stands at $10.34. The third major resistance level sits at $10.45. If the price goes on to break the first support level at $10.03, it is likely to go to the next support level at $9.92. Assuming the price breaks the second support level, the third support level stands at $9.82.
Roivant Sciences Ltd (NASDAQ: ROIV) Key Stats
Market capitalization of the company is 7.24 billion based on 713,549K outstanding shares. Right now, sales total 124,800 K and income totals 4,349 M. The company made 9,020 K in profit during its latest quarter, and 169,380 K in sales during its previous quarter.
